according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 1.24
 28.09.2024
 68434-00025
 Date of first issue: 27.02.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Letermovir Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Pharmaceutical

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Piercetown

A86 HD21 Dunboyne, Ireland

Telephone : 908-740-4000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Additional Labelling

EUH210 Safety data sheet available on request.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 1.24 28.09.2024 68434-00025 Date of first issue: 27.02.2015

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Letermovir	917389-32-3	Repr. 2; H361d	>= 1 - < 3
		STOT RE 2; H373	
		(Liver, spleen, Blood)	

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 1.24 28.09.2024 68434-00025 Date of first issue: 27.02.2015

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting. If swallowed

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

None known.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

5.3 Advice for firefighters

for firefighters

Special protective equipment : In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 1.24
 28.09.2024
 68434-00025
 Date of first issue: 27.02.2015

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 1.24 28.09.2024 68434-00025 Date of first issue: 27.02.2015

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Letermovir	917389-32- 3	TWA	0.4 mg/m3 (OEB 2)	Internal

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less guick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Skin and body protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to I.S. EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 1.24 28.09.2024 68434-00025 Date of first issue: 27.02.2015

Physical state : liquid

Colour : clear

Odour : odourless

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : 7.5

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 1.24
 28.09.2024
 68434-00025
 Date of first issue: 27.02.2015

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact Ingestion

Eye contact

Acute toxicity

Not classified based on available information.

Components:

Letermovir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 1.24
 28.09.2024
 68434-00025
 Date of first issue: 27.02.2015

Components:

Letermovir:

Remarks : No data available

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Letermovir:

Remarks : No data available

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Letermovir:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Letermovir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 1.24 28.09.2024 68434-00025 Date of first issue: 27.02.2015

Components:

Letermovir:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, female Application Route: Oral

Fertility: NOAEL: 240 mg/kg body weight

Result: No effects on fertility

Test Type: Fertility/early embryonic development

Species: Rat, male Application Route: Oral

Fertility: LOAEL: 180 mg/kg body weight

Result: No effects on fertility

Remarks: The significance of these findings for humans is not

certain.

Test Type: Fertility/early embryonic development

Species: Monkey, male Application Route: Oral

Fertility: NOAEL: 240 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Developmental Toxicity: LOAEL: 250 mg/kg body weight

Result: Embryo-foetal toxicity

Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development

Species: Rabbit

Developmental Toxicity: LOAEL: 225 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.,

Abortion

Remarks: Maternal toxicity observed.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

Letermovir:

Exposure routes : Ingestion

Target Organs : Liver, spleen, Blood

Assessment : May cause damage to organs through prolonged or repeated

exposure.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 1.24
 28.09.2024
 68434-00025
 Date of first issue: 27.02.2015

Repeated dose toxicity

Components:

Letermovir:

Species: MouseNOAEL: 40 mg/kgLOAEL: 100 mg/kgApplication Route: OralExposure time: 13 WeeksTarget Organs: Liver, spleen

Species : Rat
NOAEL : 150 mg/kg
Application Route : Oral
Exposure time : 26 Weeks

Remarks : No significant adverse effects were reported

Species : Monkey
NOAEL : 100 mg/kg
LOAEL : 200 - 250 mg/kg

Application Route : Oral
Exposure time : 39 Weeks
Target Organs : Kidney

Species : Rat
NOAEL : 60 mg/kg
LOAEL : 180 mg/kg
Exposure time : 13 Weeks

Target Organs : Testis, Blood, Liver, spleen, Immune system

Species : Monkey
NOAEL : 30 mg/kg
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 4 Weeks
Target Organs : Blood

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 1.24
 28.09.2024
 68434-00025
 Date of first issue: 27.02.2015

Experience with human exposure

Components:

Letermovir:

Ingestion : Symptoms: Diarrhoea, Nausea, Vomiting, Headache, Dizzi-

ness, Fatigue, Back pain, Oedema, Rash, muscle pain

SECTION 12: Ecological information

12.1 Toxicity

Components:

Letermovir:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): 16 mg/l

Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 8.8

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 8.8

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 972 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 29.6 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox-

icity)

NOEC: 1 mg/l

Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 1.24 28.09.2024 68434-00025 Date of first issue: 27.02.2015

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 1.2 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

12.2 Persistence and degradability

Components:

Letermovir:

Biodegradability Result: rapidly degradable

> Biodegradation: 50 % Exposure time: 6.7 d

12.3 Bioaccumulative potential

Components:

Letermovir:

Partition coefficient: n-

octanol/water

log Pow: 2.29

12.4 Mobility in soil

Components:

Letermovir:

Distribution among environ-

mental compartments

: log Koc: 3.46

12.5 Results of PBT and vPvB assessment

Product:

Assessment This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment The substance/mixture does not contain components consid-

> ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 1.24 28.09.2024 68434-00025 Date of first issue: 27.02.2015

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 1.24 28.09.2024 68434-00025 Date of first issue: 27.02.2015

IATA (Cargo) Not regulated as a dangerous good IATA (Passenger) Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on

the market and use of certain dangerous substances,

mixtures and articles (Annex XVII)

REACH - Candidate List of Substances of Very High Not applicable

Concern for Authorisation (Article 59).

Regulation (EC) on substances that deplete the ozone Not applicable

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

Regulation (EU) No 649/2012 of the European Parlia-

ment and the Council concerning the export and import

of dangerous chemicals

REACH - List of substances subject to authorisation

(Annex XIV) Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Not applicable

The components of this product are reported in the following inventories:

AICS not determined

DSL not determined

IECSC not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

: Not applicable

Not applicable

Not applicable

: Not applicable

lines.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 1.24 28.09.2024 68434-00025 Date of first issue: 27.02.2015

Full text of H-Statements

H361d : Suspected of damaging the unborn child.

H373 : May cause damage to organs through prolonged or repeated

exposure if swallowed.

Full text of other abbreviations

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to : compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 1.24 28.09.2024 68434-00025 Date of first issue: 27.02.2015

to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN